New hope to stop dangerous transplant complication
NCT ID NCT04022239
Summary
This early-stage trial is testing whether a chemotherapy drug called bendamustine can safely prevent graft-versus-host disease (GVHD) in patients receiving stem cell transplants for blood cancers. GVHD occurs when donor cells attack the patient's body, and this study aims to find the best dose and schedule of bendamustine, sometimes combined with another drug, to stop this from happening. The trial will enroll 25 patients to first determine safety and then see how well it controls GVHD.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.